- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07822477
A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIV
A Phase 1, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Randomized, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Parenterally Administered VH5356136 in Adult Participants Without HIV
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: US GSK Clinical Trials Call Center
- Phone Number: 877-379-3718
- Email: GSKClinicalSupportHD@gsk.com
Study Contact Backup
- Name: EU GSK Clinical Trials Call Center
- Phone Number: +44 (0) 20 89904466
- Email: GSKClinicalSupportHD@gsk.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must be 18 to 55 years of age inclusive at the time of signing the informed consent form (ICF).
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
- Participants who are able to understand and comply with protocol requirements and timetables, instructions, and protocol-stated restrictions.
- Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive).
- Participants of any sex (male or female) are eligible. A female participant (female sex assigned at birth) is eligible to participate if they are a person of non-childbearing potential (PONCBP).
- Capable of providing signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.
The criteria presented above represent a subset of the key inclusion criteria for the study. Additional criteria, restrictions, and eligibility requirements may apply as specified in the study protocol.
Exclusion Criteria:
- History or presence of, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
- History of drug hypersensitivity, delayed-type hypersensitivity or severe hypersensitivity reaction or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates study participation.
- History of or on-going high-risk behaviors that may put the participant at increased risk for HIV acquisition in the opinion of the investigator.
- Any preexisting physical or mental condition which, in the opinion of the investigator or the medical monitor, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
- Previous exposure to the parent molecule VH4524184.
- Past or intended use of over-the-counter or prescription medication within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing and for the duration of the study.
- Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of study intervention.
- Participants receiving any protocol-prohibited medication and who are unwilling or unable to switch to an alternate medication.
- Current enrolment or participation in another clinical study.
- Any acute laboratory abnormality at screening, which, in the opinion of the investigator, would preclude the participant's participation in the study of an investigational compound.
- Positive HIV antibody/antigen test.
- History of clinically relevant hepatitis within the last 6 months.
- Positive hepatitis B or hepatitis C test.
- Clinically significant cardiovascular disease..
- QT interval corrected for heart rate according to Fridericia's formula (QTcF) >450 milliseconds (msec) and >480 msec (bundle branch block).
- Blood pressure (BP) >140/90 (systolic BP/diastolic BP [SBP/DBP]).
- Resting heart rate (HR) <50 or >100 beats per minute (bpm) when vital signs are measured at Screening or Check-in.
The criteria presented above represent a subset of the key exclusion criteria for the study. Additional criteria, restrictions, and eligibility requirements may apply as specified in the study protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: VH5356136 Formulation 1
Participants will receive a single dose of VH5356136 Formulation 1 administered on Day 1.
|
Participants will receive VH5356136 Formulation 1 on Day 1.
|
|
Placebo Comparator: Placebo for VH5356136 Formulation 1
Participants will receive a single dose of placebo for VH5356136 Formulation 1 administered on Day 1.
|
Participants will receive placebo for VH5356136 Formulation 1 on Day 1.
|
|
Experimental: VH5356136 Formulation 2
Participants will receive a single dose of VH5356136 Formulation 2 administered on Day 1.
|
Participants will receive VH5356136 Formulation 2 on Day 1.
|
|
Placebo Comparator: Placebo for VH5356136 Formulation 2
Participants will receive a single dose of placebo for VH5356136 Formulation 2 administered on Day 1.
|
Participants will receive placebo for VH5356136 Formulation 2 on Day 1.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with drug-related adverse events (AEs)
Time Frame: From Day 1 to Month 18
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
A drug-related AE is an AE that, in the opinion of the investigator, is related to one of the study interventions.
|
From Day 1 to Month 18
|
|
Number of participants with Grade 2 to Grade 5 AEs
Time Frame: From Day 1 to Month 18
|
The grading of AEs is performed based on the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading scale, here Grade 2 = moderate, Grade 3=severe, Grade 4 = potentially life-threatening, Grade 5 = death.
|
From Day 1 to Month 18
|
|
Number of participants with serious adverse events (SAEs)
Time Frame: From Day 1 to Month 18
|
An SAE is defined as any untoward medical occurrence that results in death, are life threatening, require hospitalization or prolongation of hospitalization or results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes.
|
From Day 1 to Month 18
|
|
Area under the concentration time curve from zero (pre-dose) to the last quantifiable concentration (post dose) (AUC[0-tlast]) for VH5356136
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
AUC(0-tlast) for VH4524184
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
Maximum plasma concentration (Cmax) for VH5356136
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
Cmax for VH4524184
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
Time to maximum observed plasma drug concentration (tmax) for VH5356136
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
Tmax for VH4524184
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
Terminal half-life (t1/2) for VH5356136
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
t1/2 for VH4524184
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with Grade 3 and Grade 4 laboratory abnormalities
Time Frame: From Day 1 (pre-dose) up to Month 18 post-dose
|
The laboratory abnormalities are assessed using the DAIDS grading scale, where Grade 3 = severe and Grade 4 = potentially life-threatening.
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Blood-Borne Infections
- Urogenital Diseases
- Genital Diseases
- Immune System Diseases
- Infections
- RNA Virus Infections
- Virus Diseases
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- HIV Infections
Other Study ID Numbers
- 300862
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.